Patents Examined by Jegatheesan Seharaseyon
  • Immunomodulatory peptides and methods of use thereof
    Patent number: 10550171
    Abstract: The present disclosure provides peptides that modulate an immune response in an individual. The present disclosure provides peptides that modulate cellular responses in vitro. The present disclosure provides compositions comprising the peptides. The peptides and compositions are useful in methods of modulating an immune response in an individual, which methods are also provided.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: February 4, 2020
    Assignee: The Governors of the University of Alberta
    Inventors: Adrian Egli, Deanna Michelle Santer, Aviad Yaagov Levin, Bradley Scott Thomas, Khaled Hassan Sayed Barakat, Michael A. Joyce, Daire Thomas O'Shea, Rakesh Kumar Bhat, Michael Houghton, D. Lorne J. Tyrrell, Atul Humar, Deepali Kumar
  • Interferon alpha 2B variants
    Patent number: 10544199
    Abstract: The present invention provides a fusion polypeptide comprising a first domain and a second domain, wherein the first domain comprises a polypeptide ligand which binds to a cell surface-associated antigen and the second domain comprises aglycosylated interferon ? 2b (IFN?2b) having a sequence of SEQ ID NO: 1 or SEQ ID NO: 2. The aglycosylated IFN?2b further comprises one or more amino acid substitutions or deletions which attenuate the activity of the aglycosylated IFN?2b.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: January 28, 2020
    Assignee: Teva Pharmaceuticals Australia Pty Ltd
    Inventors: Collette Behrens, Anthony Doyle, Adam Clarke, Matthew Pollard, Teresa Domagala
  • Compositions and methods relating to the treatment of diseases
    Patent number: 10487127
    Abstract: The present invention relates to compositions and methods for promoting the induction of a cell-mediated immune response (such as that mediated by Th1 cells) and the suppression of a humoral or allergic immune response (such as that mediated by Th2 and Th17 cells). In particular, the invention relates to compositions and methods for preventing or treating allergy, such as food allergy, and associated allergic diseases, and conditions where an exaggerated Th17 response plays a detrimental role. The invention further extends to the use of the compositions of the invention in the treatment and/or prophylaxis of allergy and associated allergic diseases and also of cancer.
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: November 26, 2019
    Assignee: ALFACYTE LTD
    Inventor: William Stimson
  • Pharmaceutical compositions containing, as active ingredient, granulocyte-colony stimulating factor mutant protein or transferrin fusion protein thereof
    Patent number: 10479822
    Abstract: The present invention relates to a fusion protein in which transferrin is peptide-bonded to a terminal of a granulocyte-colony stimulating factor (G-CSF) protein or a G-CSF mutant protein in which the 116th threonine is substituted with cysteine in the amino acid sequence of the G-CSF. Specifically, the granulocyte-colony stimulating factor (G-CSF) mutant protein of the present invention or the transferrin fusion protein thereof displays a significantly increased specific activity and blood stability, compared with the conventional human G-CSF, and has a higher purification efficiency than the conventional PEGylated G-CSF characterized by the extended half-life, so that it can be advantageously used for preventing or treating ischemic diseases or neutropenia.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: November 19, 2019
    Assignee: SUPEX BNP CO., LTD.
    Inventors: Jeong-Hyeok Yoon, Byung-Ha Chang, Bong-Seok Jin, Ji Young Bae, Soon Nam Kim, Kyeong Su Park, Yeong kyu Park, Hanjo Kim, Youngju Seo, Wooseong Jeong, KyungTae Kang
  • Compositions of GM-CSF and interleukin fusions for immune modulation and uses related thereto
    Patent number: 10464982
    Abstract: This disclosure relates to recombinant proteins comprising a GM-CSF sequence and an interleukin sequence and nucleic acids related thereto. In certain embodiments, the disclosure relates to recombinant proteins comprises N-terminal sequences that are the result of improved production techniques and uses for treating or preventing autoimmune diseases such as multiple sclerosis and cancer.
    Type: Grant
    Filed: April 13, 2015
    Date of Patent: November 5, 2019
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc.
    Inventors: Jacques Galipeau, Andrea Pennati
  • Interferon analogs
    Patent number: 10442845
    Abstract: The invention relates to the field of medicine. Among others, it relates to biologically active analogs of interferons (IFNs) which show less unwanted side-effects and to the therapeutic uses thereof. Provided is an IFN analog, wherein the moiety mediating binding to its natural receptor is at least functionally disrupted and wherein the analog comprises a signaling moiety capable of mediating intracellular IFN activity, said signaling moiety being provided at its N-terminus, optionally via a linker, with at least one targeting domain capable of binding to a cell surface receptor other than the IFN receptor.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: October 15, 2019
    Assignee: BiOrion Technologies B.V.
    Inventors: Klaas Poelstra, Jai Prakash, Eleonora Beljaars, Ruchi Bansal
  • Method of diagnosis and treatment
    Patent number: 10441636
    Abstract: The present invention relates generally to a method of diagnosing, prognosing or monitoring the development or progress of metastatic cancer, more particularly bone metastatic cancer. The method of the present invention more particularly provides a method for detecting metastatic cancer, or a predisposition thereto, by screening for the differential expression of a panel of genes which comprise an IRF7 binding site. In a related aspect, the present invention provides a method of therapeutically or prophylactically treating metastatic cancer, in particular bone metastatic cancer. More particularly, the present invention provides a means of therapeutically or prophylactically treating metastatic cancer by upregulating type I IFN levels.
    Type: Grant
    Filed: July 19, 2013
    Date of Patent: October 15, 2019
    Assignee: LA TROBE UNIVERSITY
    Inventors: Belinda Sheree Parker, Paul John Hertzog
  • Treatment of peripheral vascular disease using protein solutions
    Patent number: 10441634
    Abstract: Methods of treating peripheral vascular disease comprising administering a protein solution site of a defect at least two proteins from the group IL-1ra, sTNF-RI, sTNF-RII, IGF-I, EGF, HGF, PDGF-AB, PDGF-BB, VEGF, TGF-?1, and sIL-1RII. The solution may also comprise white blood cells, platelets, concentrated bone marrow aspirate, and combinations thereof.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: October 15, 2019
    Assignee: Biomet Biologics, LLC
    Inventors: Matthew D. Landrigan, Krista Toler, Jennifer E. Woodell-May, David L. Suter
  • Immunoglobulins and uses thereof
    Patent number: 10428134
    Abstract: The present invention relates to a monoclonal antibody platform designed to be coupled to therapeutic peptides to increase the half-life of the therapeutic peptide in a subject. The invention also relates to pharmaceutical compositions and methods for use thereof.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: October 1, 2019
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Mark Macielag, Raymond J Patch, Rui Zhang, Martin A Case, Shamina M Rangwala, James N Leonard, Raul C Camacho, Michael J Hunter, Katharine E. D'Aquino, Wilson Edwards, Ronald V Swanson, Wenying Jian, Yue-Mei Zhang, Mark Wall, Ellen Chi
  • Antibodies
    Patent number: 10421814
    Abstract: The present invention relates to an anti-CSF-1R antibody and binding fragments thereof, DNA encoding the same, host cells comprising said DNA and methods of expressing the antibody or binding fragment in a host cell. The present invention also extends to pharmaceutical compositions comprising the antibody or a binding fragment thereof and use of the antibody, binding fragment and compositions comprising the same in treatment.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: September 24, 2019
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Graham Craggs, Karine Jeannine Madeleine Herve, Diane Marshall
  • Amino acid substituted molecules
    Patent number: 10407482
    Abstract: The invention provides compositions and methods of identifying, modifying and producing modified target molecules, including therapeutic molecules by modification with non-natural amino acids. Certain aspects of the invention include methods of adding a chemical moiety to a target molecule, and the compositions resulting therefrom. Certain aspects of the invention also relate to kits for identifying, modifying and producing modified target molecules described herein.
    Type: Grant
    Filed: October 16, 2013
    Date of Patent: September 10, 2019
    Assignee: ALLOZYNE, INC.
    Inventors: Kenneth H. Grabstein, David A. Tirrell
  • Methods for treating or ameliorating multiple sclerosis
    Patent number: 10393758
    Abstract: The invention relates to a recombinant protein and uses thereof in the diagnosis and treatment of multiple sclerosis. The invention also relates to the recombinant protein IFNAR2.3, antibodies, compositions comprising same, and uses thereof. Among the uses thereof, the invention especially relates to a method for the diagnosis of multiple sclerosis, and to the diagnosis kit. The invention further relates to the use of the protein IFNAR2.3 in the preparation of a medicament for the treatment of multiple sclerosis.
    Type: Grant
    Filed: November 22, 2013
    Date of Patent: August 27, 2019
    Assignee: UNIVERSIDAD DE MALAGA
    Inventors: Óscar Fernández Fernández, Begoña Oliver Martos, Teresa Órpez Zafra, José Pavía Molina, Cristobalina Mayorga Mayorga, Laura Leyva Fernández, María Jesús Pinto Medel, Margarita Suardíaz García
  • Interferon receptor 1 antibodies and their uses
    Patent number: 10385133
    Abstract: The present invention provides isolated human monoclonal antibodies that bind to IFNAR-1 and that are capable of inhibiting the biological activity of Type I interferons. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting Type I interferon-mediated disorders using the antibodies of the invention, including methods for treating autoimmune disorders, transplant rejection or Graft Versus Host Disease using the antibodies of the invention.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: August 20, 2019
    Assignee: E.R. Squibb & Sons, L.L.C.
    Inventors: Josephine M. Cardarelli, Alison Witte, Mohan Srinivasan
  • Method of diagnosis and treatment
    Patent number: 10376565
    Abstract: The present invention relates generally to a method of diagnosing, prognosing or monitoring the development or progress of metastatic cancer, more particularly bone metastatic cancer. The method of the present invention more particularly provides a method for detecting metastatic cancer, or a predisposition thereto, by screening for the differential expression of a panel of genes which comprise an IRF7 binding site. In a related aspect, the present invention provides a method of therapeutically or prophylactically treating metastatic cancer, in particular bone metastatic cancer. More particularly, the present invention provides a means of therapeutically or prophylactically treating metastatic cancer by upregulating type I IFN levels.
    Type: Grant
    Filed: July 19, 2013
    Date of Patent: August 13, 2019
    Assignee: LA TROBE UNIVERSITY
    Inventors: Belinda Sheree Parker, Paul John Hertzog
  • Glycosylated polypeptide and pharmaceutical composition containing same
    Patent number: 10358470
    Abstract: The object of the present invention is to provide a glycosylated polypeptide having uniform sugar chain structure which has interferon ? activity. It was found that a glycosylated polypeptide having uniform sugar chain structure as well as having interferon ? activity can be prepared by a method comprising a step of synthesizing a glycosylated peptide fragment and at least two peptide fragments and a step of linking the glycosylated peptide fragment and the at least two peptide fragments.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: July 23, 2019
    Assignee: GLYTECH, INC.
    Inventors: Izumi Sakamoto, Kazuhiro Fukae, Katsunari Tezuka, Keisuke Tazuru, Masatoshi Maeda, Yasuhiro Kajihara, Takashi Tsuji
  • Product and method for treating sarcopenia
    Patent number: 10358502
    Abstract: A method of treating sarcopenia comprises administering to a subject a composition comprising an anti-AGE antibody. The method may also be used for preventing or delaying the onset of cataracts, preventing or delaying the onset of loss of adipose tissue, increasing health span, and preventing or delaying the onset of lordokyphosis.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: July 23, 2019
    Assignee: Siwa Corporation
    Inventor: Lewis S. Gruber
  • Interferon alpha and omega antibody antagonists
    Patent number: 10358491
    Abstract: The present invention relates to antibodies that broady neutralize interferon-? and interferon-?, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: July 23, 2019
    Assignee: Janssen Biotech, Inc.
    Inventors: Ellen Chi, Judith Connor, Chichi Huang, Jarrat Jordan, Xiefan Lin-Schmidt, Jinquan Luo, Lu Lu, Christian Martinez, Galina Obmolova, Ronald Swanson
  • Methods for reducing global chronic inflammation and the presence of melanoma
    Patent number: 10287344
    Abstract: This document relates to methods and materials involved in treating cancer (e.g., melanoma). For example, methods and materials involved in using an anti-chronic inflammation treatment (e.g., chemotherapy) in combination with a cancer treatment agent (e.g., a cancer vaccine) to treat cancer are provided.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: May 14, 2019
    Assignee: Mayo Foundation for Medical Education and Research
    Inventor: Svetomir N. Markovic
  • Yeast strains producing mammalian-like complex N-glycans
    Patent number: 10287557
    Abstract: Described herein are methods and genetically engineered fungal cells useful for producing target molecules containing mammalian-like complex N-glycans or containing intermediates in a mammalian glycosylation pathway.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: May 14, 2019
    Assignee: Oxyrane UK Limited
    Inventors: Steven Christian Jozef Geysens, Wouter Vervecken
  • Epitope recognized by anti-interferon gamma autoantibodies in patients with disseminated mycobacterial infections and the application therefor
    Patent number: 10273278
    Abstract: The present invention discloses a fragment of peptide which can be utilized in patients suffering from a disseminated mycobacterial infection. The fragment of peptide contains a sequence of amino acids with seven residues as formula (I) shown below, wherein X1 is Leucine (Leu); X2 is Proline (Pro); X3 is Glutamate (Glu); X4 is serine (Ser); X5 is Serine (Ser); X6 is Leucine (Leu) and X7 is Arginine (Arg): X1-X2-X3-X4-X5-X6-X7 (I).
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: April 30, 2019
    Assignee: CHANG GUNG UNIVERSITY
    Inventors: Cheng-Lun Ku, Chia-Hao Lin, Chih-Yu Chi, Han-Po Shih, Jing-Ya Ding